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Abstract 
A reversed phase parallel artificial membrane permeation assay (RP-PAMPA) was newly invented for log P 
measurement. An oil/water/oil sandwich was constructed using a conventional PAMPA instrument. 1 % 
agarose was used to improve the physical stability of the water phase. A linear correlation between log P 
and the apparent permeability was observed in the -0.24 < log P < 2.85 region (R
2
 = 0.98). RP-PAMPA was 
also applied to pKa measurement. 
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Introduction 
High throughput physicochemical profiling of a drug is still challenging in early drug discovery. Various 
methods have been proposed for octanol – water partition coefficient (log P), solubility, and pKa 
measurements [1]. The parallel artificial membrane permeation assay (PAMPA) has been widely used in 
drug discovery as PAMPA is compatible with high throughput screening (HTS) [2,3]. In normal phase (NP-) 
PAMPA methods, a lipid phase is immobilized on a filter (usually a 96 well filter plate) and the permeability 
of a drug across the lipid membrane is measured. Previously, Faller et al. applied NP-PAMPA to log P 
measurement [4]. The apparent permeability (Papp) across the octanol impregnated filter membrane was 
found to correlate with logP. However, the Papp – log P curve showed a bell-shaped relationship with a 
plateau around log P = 1. Therefore, it was impossible to estimate the log P values around log P = 1. A bell-
shaped relationship between Papp and lipophilicity of drugs is usually observed in NP-PAMPA [5]. 
The purpose of the present study was to overcome the drawback of NP-PAMPA for log P measurement. 
A reversed phase PAMPA (RP-PAMPA) method for log P measurement was newly invented. In RP-PAMPA, 
an oil/water/oil sandwich was constructed using a conventional PAMPA instrument (Figure 1). In addition, 
RP-PAMPA was applied for pKa measurement, especially for low solubility compounds. 
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Figure 1.  Schematic configuration of RP-PAMPA 
Materials and Methods 
Materials 
Octanol, pentoxifylline, 1-naphthol, dipyridamole, and acid blue 9 were purchased from Tokyo chemical 
industry (Tokyo, Japan). Agar powder, agarose S, agarose H, prednisone, sulfamethoxazole, carbamazepine, 
caffeine, chlormphenicol, ethanol, trisodium citrate, sodium dihydrogenphosphate, disodium 
hydrogenphosphate, sodium hydroxide solution, propranolol hydrochloride, warfarin sodium, piroxicam, 
and ketoprofen were purchased from Wako pure chemicals (Tokyo, Japan). Phenacetin was purchased from 
Yamamoto Corporation (Osaka, Japan). The other reagents were of analytical grade. 
Papp measurement 
The schematic configuration of RP-PAMPA is shown in Figure 1. In RP-PAMPA, the water phase (water 
membrane) was immobilized on the hydrophilic filter with the aid of agarose. Agarose S was dissolved in 
hot water or a buffer at 1.0 % and then poured into a hydrophilic filter (Multi Screen-HV, pore size 0.48 μm, 
low protein binding, Millipore). A model drug was dissolved in octanol at 10 mM and added to the donor 
plate (downside, 300 μL). The filter plate was then put on the donor plate. The filter plate was filled with 
200 μL of octanol. After 16 hour incubation at room temperature (25 ± 1 °C), both octanol phases were 
diluted tenfold by ethanol and the drug concentrations in the donor and accepter sides were measured by 
UV spectroscopy. For pKa measurement sodium - phosphate and sodium - citric acid buffers (100 mM of 
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where CA and CD are the drug concentrations in the donor and acceptor phases at time t, respectively. VD 
and VA are the volumes of the donor and acceptor phases, respectively. A is the membrane surface area 
(0.28 cm2). 
Results  
Construction of RP-PAMPA 
We first investigated the stability of the water phase (water membrane) constructed on the hydrophilic 
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filter with the aid of agarose. 1.0 % concentration was selected to enable pipetting of the hot sol phase 
while maintaining the physical strength of the agarose gel. It was found that at least 30 μL of 1 % agarose 
was required to provide sufficient physical strength for Papp measurement. The ager powder was found to 
form a less stable water phase compared to Agarose S and H. In a preliminary study, it was found that more 
than 10 hours were required to achieve a steady – state flux across the water phase (data not shown). 
Therefore, the Agarose S 30 μL water membrane and 16 hour incubation time were employed in the 
following studies. 
Log Papp – log P relationship 
The log Papp and log P data are summarized in Table 1 [1,7,8]. Figure 2 shows the correlation between 
log Papp and log P. A linear correlation was observed in the -0.24 < log P < 2.85 region (R
2 = 0.98). The slope 
of the log-log plot was -0.48. 
Table 1. Papp and log P 
Drug log P (literature)a log Papp (cm s
-1, mean ± S.D., N = 6) 
phenacetin 1.58 -6.38 ± 0.04 
caffeine 0.10 -5.53 ± 0.02 
carbamazepine 2.1 -6.52 ± 0.04 
prednisone 1.56 -6.25 ± 0.01 
chloramphenicol 1.14 -6.13 ± 0.01 
sulfamethoxazole 0.70 -5.96 ± 0.02 
1-naphthol 2.85 -6.95 ± 0.03 
pentoxifylline 0.38 -5.78 ± 0.02 
a
 Refs. [1,7,8] 
 
Figure 2.  Log P – log Papp relationship. 
pH - Papp profile  
The pH - Papp profiles were shown in Figure 3 and Table 2. The pKa values were obtained as the 
intersection of the slope and the horizontal lines. Estimated and literature pKa values are shown in Table 3 
[1,9]. 
y = -0.4835x - 5.5584 
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Figure 3.  pH – Papp relationship. Mean ± S.D. N = 3. 
Table 2. Papp of dissociable drugs at each pH
a
 
Compound pH Papp (10
-6 cm sec-1) Compound pH Papp (10
-6 cm sec-1) 
Ketoprofen 3.1 0.17 ± 0.03 Dipyridamole 3.9 0.31 ± 0.02 
(log P = 3.2) 3.5 0.17 ± 0.07 (log P = 3.9) 4.5 0.30 ± 0.01 
 
4.1 0.15 ± 0.05 
 
5.1 0.20 ± 0.02 
 
4.5 0.18 ± 0.04 
 
5.5 0.11 ± 0.02 
 
5.0 0.28 ± 0.09 
 
5.9 0.07 ± 0.02 
 
5.5 0.44 ± 0.10 
 
6.5 0.05 ± 0.01 
 
6.0 1.33 ± 0.18 
 
7.0 0.05 ± 0.03 
 
6.5 2.00 ± 0.23 
 
7.5 0.04 ± 0.00 
Piroxicam 3.0 0.81 ± 0.07 Propranolol 8.0 1.05 ± 0.06 
(log P = 2.0) 3.5 0.81 ± 0.19 (log P = 2.9) 8.5 0.72 ± 0.08 
 
4.0 0.77 ± 0.07 
 
9.0 0.63 ± 0.10 
 
4.5 0.68 ± 0.07 
 
9.5 0.42 ± 0.04 
 
5.0 0.81 ± 0.15 
 
10.0 0.40 ± 0.12 
 
5.5 0.98 ± 0.13 
 
10.5 0.39 ± 0.04 
 
6.0 1.62 ± 0.08 
 
11.0 0.38 ± 0.01 
 
6.5 2.37 ± 0.24 
 
11.5 0.38 ± 0.03 
Warfarin 3.0 0.16 ± 0.01 
   
(log P = 3.1) 3.5 0.16 ± 0.01 
   
 
4.0 0.16 ± 0.02 
   
 
4.5 0.23 ± 0.02 
   
 
5.0 0.22 ± 0.04 
   
 
5.5 0.23 ± 0.02 
   
 
6.0 0.34 ± 0.04 
   
 
6.5 0.80 ± 0.05 
   a Mean ± S.D. N = 3. Measured at 25 °C. The buffer concentration was 100 mM. 
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Table 3.  pKa values 
Drug This study a Literatureb 
Ketoprofen 4.9 4.0 
Piroxicam 4.8 4.7 
Warfarin 5.7 5.0 
Dipyridamole 5.9 6.1 
Propranolol 9.4 9.5 
a
 Measured at 25 °C. The buffer concentration was 100 mM. 
b
 Refs. [1], [9]. 
Discussion 
In this study, RP-PAMPA for log P measurement was investigated for the first time. 1.0 % agarose was 
used to improve the physical stability of the water membrane. The mesh size of agarose is significantly 
larger than the size of drug molecules so that it does not affect the diffusion coefficient of drugs [10]. By 
using RP-PAMPA, log P in the -0.24 < log P < 2.85 range can be accurately measured. The measurable range 
can be expanded by using a more sensitive quantitation method such as LC-MS. The slope of the Papp – log P 
relationship was 0.45, which is significantly smaller than 1. If Papp follows the solubility – partition theory for 
membrane permeation, i.e., Papp = PD/h where D is the diffusion coefficient and h is the thickness of the 
membrane, the slope of the log-log plot should be unity [11]. The reason for this deviation is not clear. 
Previously, Kwon et al. reported a poly(dimethylsiloxane)(PDMS) permeation assay, which might be 
regarded as a kind of reversed phase membrane permeation assay [12]. However, the configuration of the 
PDMS permeation assay was largely different from the one used in the present study that is usually 
referred as PAMPA. In the PDMS permeation assay, a side-by-side single diffusion chamber was employed. 
A PDMS membrane was put between two chambers filled with aqueous bulk fluids. In addition, PDMS disks 
were added to both the donor and acceptor sides as dosing and sampling (extracting) phases, respectively. 
The aqueous phases were stirred by magnetic stirrers. In the PDMS permeation assay, a good correlation 
was observed between log Papp and log P in the range of log P > 3 even though PDMS was used instead of 
octanol as the oil phase. 
For low solubility drugs, it has been difficult to measure pKa by using conventional methods such as pH 
titration. The pH – solubility profile can be used to estimate pKa for low solubility drugs [13,14]. However, 
this method may not be accurate due to aggregate formation, low detection limit, etc. In RP-PAMPA, a drug 
is solubilized in the organic solvent phase. Therefore, it would become possible to measure pKa for low 
solubility drugs by using RP-PAMPA. As the pH of the water membrane was changed in RP-PAMPA, the pH – 
Papp relationship should become a mirror image of that for NP-PAMPA. However, the pH – Papp relationship 
deviated from the Henderson – Hasselbalch equation. Therefore, the pKa values of the model drugs were 
estimated as the intersection of the slope and the horizontal lines. The pKa values of acidic drugs were 
underestimated by the RP-PAMPA method. The reason for this deviation is not clear. One possible reason 
may be that the incubation time of 16 hours might not be sufficient to achieve a steady state at pH > pKa for 
acids. The pKa of diclofenac has been reported to be ca. 4.0 in most cases in the literature. However, pKa of 
5.7 was obtained from the pH-solubility profile [15]. The Papp value at a pH where a drug molecule is 
undissociable (intrinsic water permeability, Pw,int) also correlated with log P. However, Pw,int deviated from 
the log Papp – log P line for the undissociable drugs about 0.3 log unit. The difference of the water 
membrane (pure water vs. a buffer) could be a reason for the discrepancy. The present RP-PAMPA method 
ADMET & DMPK 4(1) (2016) 54-59 Reversed phase PAMPA 
doi: 10.5599/admet.4.1.277 59 
needs to be improved for pKa measurement in the future. 
In conclusion, in the present study, RP-PAMPA for log P measurement was constructed for the first time. 
1.0 % agarose can be used to stabilize the water membrane. RP-PAMPA was applied to log P and pKa 
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